Welcome to LookChem.com Sign In|Join Free

CAS

  • or

5318-27-4

Post Buying Request

5318-27-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5318-27-4 Usage

Description

6-Aminoindole is an organic compound with the molecular formula C8H8N2. It is a solid substance that serves as a crucial building block in the synthesis of various biologically active molecules and pharmaceuticals. Its chemical structure features an indole ring with an amino group attached at the 6th position, which contributes to its diverse reactivity and applications in different industries.

Uses

Used in Pharmaceutical Industry:
6-Aminoindole is used as a reactant for the preparation of various inhibitors and blockers, playing a significant role in the development of new drugs for treating different medical conditions. Its applications include:
1. Inhibitors of mammalian target of rapamycin (mTOR) protein: These inhibitors are essential in the treatment of various cancers by regulating cell growth and proliferation.
2. Inhibitors of the AcrAB-TolC efflux pump: These inhibitors help combat antibiotic resistance by preventing the efflux of antibiotics from bacterial cells.
3. Inhibitors of Gli1-mediated transcription in the Hedgehog pathway: These inhibitors are crucial in the treatment of certain cancers and congenital disorders by targeting the Hedgehog signaling pathway.
4. Potent DNA-topoisomerase II poisons and anti-MDR agents: These agents are used to inhibit the activity of DNA-topoisomerase II, a crucial enzyme in DNA replication, and to overcome multidrug resistance in cancer cells.
5. Protein kinase C θ (PKCθ) inhibitors: These inhibitors are involved in the regulation of immune cell activation and are being explored for their potential in treating autoimmune diseases and cancer.
Used in Pain Management:
6-Aminoindole is used as a building block for the development of potent and selective blockers of the Nav1.8 sodium channel, which are potential analgesics for the treatment of neuropathic and inflammatory pain.
Used in TRPV1 Antagonists:
6-Aminoindole is used as a reactant for the synthesis of piperidine carboxamide and 5,6-fused heteroaromatic ureas, which are TRPV1 antagonists. These antagonists have potential applications in the treatment of pain, inflammation, and other conditions related to the transient receptor potential cation channel subfamily V member 1 (TRPV1).
Used in Allosteric Enhancers:
6-Aminoindole is used as a reactant for the preparation of allosteric enhancers of the A3 adenosine receptor, which have potential therapeutic applications in various diseases, including cancer, inflammation, and neurodegenerative disorders.
Used in Type 2 Diabetes Treatment:
6-Aminoindole is used as a reactant for the synthesis of human liver glycogen phosphorylase (HLGP) inhibitors, which are being investigated for their potential in the treatment of type 2 diabetes by regulating glucose metabolism.

Check Digit Verification of cas no

The CAS Registry Mumber 5318-27-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,3,1 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 5318-27:
(6*5)+(5*3)+(4*1)+(3*8)+(2*2)+(1*7)=84
84 % 10 = 4
So 5318-27-4 is a valid CAS Registry Number.
InChI:InChI=1/C18H20ClN3O2/c1-3-22(4-2)16-9-8-14(17(23)11-16)12-20-21-18(24)13-6-5-7-15(19)10-13/h5-12,20H,3-4H2,1-2H3,(H,21,24)/b14-12+

5318-27-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (L17793)  6-Aminoindole, 98%   

  • 5318-27-4

  • 100mg

  • 451.0CNY

  • Detail
  • Alfa Aesar

  • (L17793)  6-Aminoindole, 98%   

  • 5318-27-4

  • 500mg

  • 1681.0CNY

  • Detail
  • Aldrich

  • (630721)  6-Aminoindole  97%

  • 5318-27-4

  • 630721-1G

  • 823.68CNY

  • Detail
  • Aldrich

  • (630721)  6-Aminoindole  97%

  • 5318-27-4

  • 630721-5G

  • 3,162.51CNY

  • Detail

5318-27-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1H-indol-6-amine

1.2 Other means of identification

Product number -
Other names Indol-6-ylamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5318-27-4 SDS

5318-27-4Relevant articles and documents

Structure-based drug design, synthesis, In vitro, and In vivo biological evaluation of indole-based biomimetic analogs targeting estrogen receptor-α inhibition

Hendy, Moataz S.,Ali, Aya A.,Ahmed, Lubna,Hossam, Reham,Mostafa, Alaa,Elmazar, Mohamed M.,Naguib, Bassem H.,Attia, Yasmeen M.,Ahmed, Mahmoud Salama

, p. 281 - 290 (2019)

Offering novel scaffolds targeting estrogen receptor creates huge necessity to overcome the evolving resistance developed by tumors. Structure-based drug design coupled with ring opening strategy of the steroids skeleton revealed the potential of indole-based analogs to be synthesized targeting the ligand binding domain of estrogen receptor-α. In vitro studies revealed the potential of the total sub-classes of the synthesized analogs to show anti-proliferative activity against estrogen receptor-dependent cancer cell lines at IC50 ranging from 28.23 to 57.13 μM. This was further validated by evaluating the potential of the synthesized analogs to compete along with estradiol via ER-α ELISA assay to show inhibitory profile at IC50 ranging from 1.76 to 204.75 nM. Two analogs (YMA-005 and YMA-006) showed significant reduction in tumor size at two dose levels with extensive degeneration and necrosis. Both YMA-005 and YMA-006 showed in-situ reduction of ER-α Immunohistochemical expression at both dose levels. Ultimately, novel analogs of indole-based biomimetic of estrone scaffolds were offered as estrogen receptor-α inhibitors.

COPPER NANOPARTICLE BASED CHEMOSELECTIVE REDUCTION

-

Paragraph 0050; 0051, (2021/11/20)

The instant invention provides processes for a chemo selective reduction of a nitro group within a compound in the presence of other groups which can also be reduced. This aspect of the present invention provides an ammonia borane (AB) initiated chemoselective reduction process of a nitro group contained within a compound in the presence of a copper (Cu) nanoparticle based catalyst. The invention is also directed to Copper (Cu) nanoparticle (NP) based catalysts, selected from Cu/WOx, Cu/SiO2, and Cu/C; wherein x represents an integer having a value of from about 2 to about 3.5, used in the chemo selective reduction of a nitro group contained within a compound in the presence of other groups which can also be reduced.

Flexible Versus Rigid G-Quadruplex DNA Ligands: Synthesis of Two Series of Bis-indole Derivatives and Comparison of Their Interactions with G-Quadruplex DNA

Prasad, Bagineni,Jamroskovic, Jan,Bhowmik, Sudipta,Kumar, Rajendra,Romell, Tajanena,Sabouri, Nasim,Chorell, Erik

supporting information, p. 7926 - 7938 (2018/06/15)

Small molecules that target G-quadruplex (G4) DNA structures are not only valuable to study G4 biology but also for their potential as therapeutics. This work centers around how different design features of small molecules can affect the interactions with G4 DNA structures, exemplified by the development of synthetic methods to bis-indole scaffolds. Our synthesized series of bis-indole scaffolds are structurally very similar but differ greatly in the flexibility of their core structures. The flexibility of the molecules proved to be an advantage compared to locking the compounds in the presumed bioactive G4 conformation. The flexible derivatives demonstrated similar or even improved G4 binding and stabilization in several orthogonal assays even though their entropic penalty of binding is higher. In addition, molecular dynamics simulations with the c-MYC G4 structure showed that the flexible compounds adapt better to the surrounding. This was reflected by an increased number of both stacking and polar interactions with both the residues in the G4 DNA structure and the DNA residues just upstream of the G4 structure.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5318-27-4